We previously reported a novel drug delivery system, drug-linker-Phe-Phe-Arg-methylketone (FFR-mk)-factor VIIa (fVIIa). The method utilizes tissue factor (TF), which is aberrantly and abundantly expressed on many cancer cells. The advantage of this delivery system is its ability to furnish a potent anticancer drug specifically to the tumor vasculature and cancer cells. In this paper, we describe the synthesis of paclitaxel (PTX)-Phe-Phe-Arg-chloromethyl ketone (FFR-ck), followed by coupling with fVIIa to form PTX-FFR-mk-fVIIa. FFRck was separately linked to the OH groups at the C2' or C7 positions of PTX (C2'- or C7-PTX-FFRck), the C2' analogue exhibiting better activity against human head and neck squamous KB 3-1 cells. The activity order against PTX-sensitive KB 3-1 cells is C2'-PTX-FFRmk-fVIIa > PTX > C2'-PTX-FFRck. The C2' complex shows an IC(50) of 12 nM against the PTX-sensitive cell line and 130 nM against PTX-resistant cells.
We previously reported a novel drug delivery system, drug-linker-Phe-Phe-Arg-methylketone (FFR-mk)-factor VIIa (fVIIa). The method utilizes n class="Gene">tissue factor (TF), which is aberrantly and abundantly expressed on many cancer cells. The advantage of this delivery system is its ability to furnish a potent anticancer drug specifically to the tumor vasculature and cancer cells. In this paper, we describe the synthesis of paclitaxel (PTX)-Phe-Phe-Arg-chloromethyl ketone (FFR-ck), followed by coupling with fVIIa to form PTX-FFR-mk-fVIIa. FFRck was separately linked to the OH groups at the C2' or C7 positions of PTX (C2'- or C7-PTX-FFRck), the C2' analogue exhibiting better activity against human head and neck squamous KB 3-1 cells. The activity order against PTX-sensitive KB 3-1 cells is C2'-PTX-FFRmk-fVIIa > PTX > C2'-PTX-FFRck. The C2' complex shows an IC(50) of 12 nM against the PTX-sensitive cell line and 130 nM against PTX-resistant cells.
Authors: Iwao Ojima; Xudong Geng; Xinyuan Wu; Chuanxing Qu; Christopher P Borella; Hongsheng Xie; Sharon D Wilhelm; Barbara A Leece; Laura M Bartle; Victor S Goldmacher; Ravi V J Chari Journal: J Med Chem Date: 2002-12-19 Impact factor: 7.446
Authors: W Mellado; N F Magri; D G Kingston; R Garcia-Arenas; G A Orr; S B Horwitz Journal: Biochem Biophys Res Commun Date: 1984-10-30 Impact factor: 3.575
Authors: Changhui Liu; Jeannine S Strobl; Susan Bane; Jennifer K Schilling; Meredith McCracken; Sabarni K Chatterjee; Rayhana Rahim-Bata; David G I Kingston Journal: J Nat Prod Date: 2004-02 Impact factor: 4.050
Authors: Pamela T Wong; Shengzhuang Tang; Jayme Cannon; Jhindan Mukherjee; Danielle Isham; Kristina Gam; Michael Payne; Sean A Yanik; James R Baker; Seok Ki Choi Journal: Chembiochem Date: 2016-11-30 Impact factor: 3.164
Authors: Shijun Zhu; Walter Kisiel; Yang J Lu; Lars C Petersen; John M Ndungu; Terry W Moore; Ernest T Parker; Aiming Sun; Jann N Sarkaria; James P Snyder; Dennis C Liotta; Daniel J Brat; Bassel F El-Rayes; Mamoru Shoji Journal: J Drug Target Date: 2014-12-16 Impact factor: 5.121
Authors: Jafar Ai; Esmaeil Biazar; Mostafa Jafarpour; Mohamad Montazeri; Ali Majdi; Saba Aminifard; Mandana Zafari; Hanie R Akbari; Hadi Gh Rad Journal: Int J Nanomedicine Date: 2011-05-31
Authors: Shijun Zhu; Walter Kisiel; Yang J Lu; Lars C Petersen; John M Ndungu; Terry W Moore; Ernest T Parker; Aiming Sun; Dennis C Liotta; Bassel F El-Rayes; Daniel J Brat; James P Snyder; Mamoru Shoji Journal: J Drug Deliv Date: 2014-12-07